Glioma risk in relation to serum levels of insulin-like growth factors

Cancer Epidemiology Biomarkers and Prevention

Volumn 16, Issue 4, 2007, Pages 844-846

  Lönn, Stefan ^a   Inskip, Peter D ^a   Pollak, Michael N ^b   Weinstein, Stephanie J ^a   Virtamo, Jarmo ^c   Albanes, Demetrius ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER RISK; CARCINOGENESIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLIOMA; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

BRAIN NEOPLASMS; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLIOMA; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; RISK; TUMOR MARKERS, BIOLOGICAL;

EID: 34247528590     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-06-1010     Document Type: Article

References (26)

1. Russo VC, Gluckman PD, Feldman EL, Werther GA. The insulin-like growth factor system and its pleiotropic functions in brain. Endocr Rev 2005;26:916-43.
2. Baserga R. The contradictions of the insulin-like growth factor 1 receptor. Oncogene 2000;19:5574-81.
3. Singleton JR, Randolph AE, Feldman EL. Insulin-like growth factor I receptor prevents apoptosis and enhances neuroblastoma tumorigenesis. Cancer Res 1996;56:4522-9.
4. Surmacz E, Guvakova MA, Nolan MK, Nicosia RF, Sciacca L. Type I insulin-like growth factor receptor function in breast cancer. Breast Cancer Res Treat 1998;47:255-67.
5. Wolk A, Mantzoros CS, Andersson SO, et al. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst 1998;90:911-5.
6. Mantzoros CS, Tzonou A, Signorello LB, Stampfer M, Trichopoulos D, Adami HO. Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer 1997;76:1115-8.
7. Yu H, Spitz MR, Mistry J, Gu J, Hong WK, Wu X. Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst 1999;91:151-6.
8. Hankinson SE, Willett WC, Colditz GA, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998;351:1393-6.
9. Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998;279:563-6.
10. Serel TA, Kecelioglu M. Serum insulin-like growth factor is not a useful marker of prostate cancer. BJU Int 2000;85:559-60.
11. Woodson K, Tangrea JA, Pollak M, Copeland TD, Taylor PR, Virtamo J, Albanes D. Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men. Cancer Res 2003;63:3991-4.
12. Stolzenberg-Solomon RZ, Limburg P, Pollak M, Taylor PR, Virtamo J, Albanes D. Insulin-like growth factor (IGF)-1, IGF-binding protein-3, and pancreatic cancer in male smokers. Cancer Epidemiol Biomarkers Prev 2004;13:438-44.
13. Zumkeller W, Westphal M. The IGF/IGFBP system in CNS malignancy. Mol Pathol 2001;54:227-9.
14. Glick RP, Lichtor T, Unterman TG. Insulin-like growth factors in central nervous system tumors. J Neurooncol 1997;35:315-25.
15. Han VK, Lauder JM, D'Ercole AJ. Characterization of somatomedin/insulin- like growth factor receptors and correlation with biologic action in cultured neonatal rat astroglial cells. J Neurosci 1987;7:501-11.
16. Tranque PA, Calle R, Naftolin F, Robbins R. Involvement of protein kinase-C in the mitogenic effect of insulin-like growth factor-I on rat astrocytes. Endocrinology 1992;131:1948-54.
17. Aberg ND, Blomstrand F, Aberg MA, et al. Insulin-like growth factor-I increases astrocyte intercellular gap junctional communication and connexin43 expression in vitro. J Neurosci Res 2003;74:12-22.
18. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995;16:3-34.
19. Daftary SS, Gore AC. IGF-1 in the brain as a regulator of reproductive neuroendocrine function. Exp Biol Med (Maywood) 2005;230:292-306.
20. Wang H, Fuller GN, Zhang W. Insulin-like growth factors and insulin-like growth factors binding proteins in CNS tumors. In: Zhang W, Fuller GN, editors. Genomic and molecular neuro-oncology. Sudbury: Jones and Bartlett Publishers; 2004. p. 119-30.
21. The ATBC Cancer Prevention Study Group. The α-tocopherol, β-carotene lung cancer prevention study: design, methods, participant characteristics, and compliance. Ann Epidemiol 1994;4:1-10.
22. The Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and β carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994;330:1029-35.
23. Baris D, Gridley G, Ron E, et al. Acromegaly and cancer risk: a cohort study in Sweden and Denmark. Cancer Causes Control 2002;13:395-400.
24. Lonn S, Klaeboe L, Hall P, et al. Incidence trends of adult primary intracerebral tumors in four Nordic countries. Int J Cancer 2004;108:450-5.
25. Spitz MR, Barnett MJ, Goodman GE, Thornquist MD, Wu X, Pollak M. Serum insulin-like growth factor (IGF) and IGF-binding protein levels and risk of lung cancer: a case-control study nested in the β-Carotene and Retinol Efficacy Trial Cohort. Cancer Epidemiol Biomarkers Prev 2002;11:1413-8.
26. Chen C, Freeman R, Voigt LF, Fitzpatrick A, Plymate SR, Weiss NS. Prostate cancer risk in relation to selected genetic polymorphisms in insulin-like growth factor-I, insulin-like growth factor binding protein-3, and insulin-like growth factor-1 receptor. Cancer Epidemiol Biomarkers Prev 2006;15:2461-6.